PolyPid (PYPD) Q1 2026 earnings summary

Executive summary

• Transitioned from late-stage clinical development to final NDA regulatory submission for D-PLEX100, targeting prevention of surgical site infections in abdominal colorectal surgery; NDA completion expected imminently.

• U.S. commercial partnership discussions are in late stages, with a launch targeted for Q1 2027.

• European regulatory strategy advancing, with EMA meetings scheduled in Q2 2026 and MAA submission planned for Q3 2026.

• Manufacturing and inspection readiness prioritized, including multiple mock inspections and external consultant engagement.

• Presented new Phase 3 clinical and pharmacokinetic data showing 64% relative risk reduction in severe wound infections and supporting D-PLEX100's efficacy and mechanism.

Financial highlights

• Q1 2026 R&D expenses were $5.8M, down from $6.1M in Q1 2025, reflecting transition from clinical to regulatory/commercial activities.

• G&A expenses rose to $1.6M from $1.2M year-over-year; marketing/business development expenses increased to $0.4M from $0.3M.

• Net loss for Q1 2026 was $7.7M ($0.35/share), improved from $8.3M ($0.70/share) in Q1 2025.

• Cash and equivalents were $10.9M as of March 31, 2026, down from $12.9M at year-end 2025.

Outlook and guidance

• Existing cash resources expected to fund operations into the second half of 2026 and through several key milestones.

• NDA submission completion imminent; FDA priority review possible due to Fast Track and Breakthrough Therapy designations, with PDUFA target action date to be set after NDA acceptance and launch planned for Q1 2027.

• EMA meetings in Q2 2026 and MAA submission to EMA targeted for Q3 2026, subject to regulatory meetings.